In this study, we investigated for the first time the impact of CPFE on AE-related lethality and prognosis in LC patients and found significant differences in EGFR mutation rates in patients with IPF combined with adenocarcinoma, which provides a new direction for an in-depth understanding of the molecular mechanisms and clinical management of this disease. This evidence concerns the gene EGFR and idiopathic pulmonary fibrosis.